


## Mogroside V

<b>Cat. No.:</b>	HY-N0502
<b>CAS No.:</b>	88901-36-4
<b>Molecular Formula:</b>	C <sub>60</sub> H <sub>102</sub> O <sub>29</sub>
<b>Molecular Weight:</b>	1287.43
<b>Target:</b>	Reactive Oxygen Species
<b>Pathway:</b>	Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
<b>Storage:</b>	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (77.67 mM; Need ultrasonic)  
H<sub>2</sub>O : 50 mg/mL (38.84 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	0.7767 mL	3.8837 mL	7.7674 mL
	5 mM	0.1553 mL	0.7767 mL	1.5535 mL
	10 mM	0.0777 mL	0.3884 mL	0.7767 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.08 mg/mL (1.62 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.08 mg/mL (1.62 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.08 mg/mL (1.62 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Mogroside V is the major active constituent of a traditional Chinese medicine *Siraitiae Fructus*. Mogroside V reduces the intracellular reactive oxygen species (ROS) levels and enhances mitochondrial function. Mogroside V has anti-oxidative, anti-diabetic and anti-carcinogenic effects. Mogroside V can be used for diabetic diseases research<sup>[1][3]</sup>.

#### In Vitro

Mogroside V (20 μM, 40 h) reduces the ROS levels in in vitro maturation (IVM) oocytes<sup>[1]</sup>.  
Mogroside V (20 μM, 40 h) can enhance mitochondrial function in oocytes<sup>[1]</sup>.  
Mogroside V (1-250 μM, 24 h) promotes apoptosis and cell cycle arrest of pancreatic cancer cells (PANC-1 cells) and may be mediated through regulating the STAT3 signaling pathway<sup>[3]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

#### Immunofluorescence<sup>[1]</sup>

Cell Line:	IVM oocytes
Concentration:	20 $\mu$ M
Incubation Time:	40 h
Result:	Increased the fluorescence intensity compared to control group. Increased the red/green fluorescence intensity ratio compared to control group.

#### Real Time qPCR<sup>[1]</sup>

Cell Line:	IVM oocytes
Concentration:	20 $\mu$ M
Incubation Time:	40 h
Result:	Increased the relative mRNA expression of SOD, CAT, PGC-1 $\alpha$ and TFAM than in control group.

#### Cell Viability Assay<sup>[3]</sup>

Cell Line:	PANC-1 cells
Concentration:	1-250 $\mu$ M
Incubation Time:	24 h
Result:	Increased the percentage of TUNEL-positive cells ranging from 2.91% to 92.25%.

#### Apoptosis Analysis<sup>[3]</sup>

Cell Line:	PANC-1 cells
Concentration:	1-250 $\mu$ M
Incubation Time:	24 h
Result:	Induced apoptosis in PANC-1 cells in a concentration- and time-dependent manner

#### Western Blot Analysis<sup>[3]</sup>

Cell Line:	PANC-1 cells
Concentration:	0-250 $\mu$ M
Incubation Time:	24 h
Result:	Increased the expression of the cyclin kinase inhibitors CDKN1A (p21 <sup>WAF1</sup> ) and CDKN1B (p27) in a dose-dependent manner. Decreased the the expression of the pro-proliferative cell cycle regulators CCND1 (cyclin D1), CCNE1 (cyclin E1) and CDK2. Suppressed phosphorylation of the kinases upstream of STAT3, including that of JAK2 and TYK2.

#### In Vivo

Mogroside V (100 mg/kg for Oral administration) transforms to 26 metabolites by the process of dehydrogenation,

---

deoxidation, oxidation and isomerization in type 2 diabetes (T2D) model rats<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	T2D model rats <sup>[2]</sup>
Dosage:	100 mg/kg
Administration:	Oral gavage (p.o.)
Result:	Detected 28 metabolites of mogroside V compared to the blank biological samples. Displayed larger peak areas of metabolites in T2D rat plasma samples than those in healthy sample.

---

## REFERENCES

- [1]. Nie J, et al. Mogroside V improves porcine oocyte in vitro maturation and subsequent embryonic development. *Theriogenology*. 2020 Jan 1;141:35-40.
- [2]. Zhou G, et al. The metabolism of a natural product mogroside V, in healthy and type 2 diabetic rats. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2018 Mar 15;1079:25-33.
- [3]. Liu C, et al. A natural food sweetener with anti-pancreatic cancer properties. *Oncogenesis*. 2016 Apr 11;5(4):e217.
- [4]. Itkin M, et al. The biosynthetic pathway of the nonsugar, high-intensity sweetener mogroside V from *Siraitia grosvenorii*. *Proc Natl Acad Sci U S A*. 2016 Nov 22;113(47):E7619-E7628.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA